Multiple sclerosis (MS) is a debilitating neuroimmunological and neurodegenerative disease (MS [MIM 126200]) and is estimated to affect 400 000 individuals in the United States alone. Numerous ...
The CEMIP enzyme inhibits the growth of oligodendrocytes and may serve as a therapeutic target to boost myelin repair in MS, ...
Multiple sclerosis (MS [MIM 126200]) is a neurodegenerative autoimmune disease characterized by demyelination within the central nervous system (CNS). Demyelination and the resulting formation of scar ...
Sanofi (SNY) stock is in focus as the company agrees to acquire Dynavax Technologies (DVAX) and the FDA rejects its multiple ...
Sanofi provides update on tolebrutinib regulatory submission in non-relapsing secondary progressive multiple sclerosis Paris, December 24, 2025. The US Food and Drug Administration (FDA) has issued a ...
Learn 10 key facts about multiple sclerosis, including symptoms, treatments, diagnosis, and ways to manage the condition and live well.
People typically develop multiple sclerosis between ages 20 and 40, but late-onset MS affects those 50 years and older. Your doctor can best diagnose and advise on possible treatments, such as ...
The over-the-counter supplement lipoic acid may have a small beneficial effect in slowing the loss of gray matter in the ...
A U.S. regulatory decision on tolebrutinib will again be delayed while a late-stage trial of the drug for a different form of ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback